1. Home
  2. ISPC vs CDT Comparison

ISPC vs CDT Comparison

Compare ISPC & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iSpecimen Inc.

ISPC

iSpecimen Inc.

HOLD

Current Price

$0.25

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.70

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPC
CDT
Founded
2009
2019
Country
United States
United States
Employees
24
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ISPC
CDT
Price
$0.25
$0.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
934.2K
435.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,291,115.00
N/A
Revenue This Year
$35.93
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.37
52 Week High
$2.16
$6.00

Technical Indicators

Market Signals
Indicator
ISPC
CDT
Relative Strength Index (RSI) 37.70 30.10
Support Level N/A $0.53
Resistance Level $0.44 $1.16
Average True Range (ATR) 0.03 0.11
MACD -0.00 -0.02
Stochastic Oscillator 14.02 15.61

Price Performance

Historical Comparison
ISPC
CDT

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: